In contrast to the findings of Scagliotti et al. [5] and Udagawa et al. [5,6] (Scagliotti et al., 2012; Udagawa et al., 2017) [5,6], in the current study, we found that denosumab had no prognostic effects in patients with lung adenocarcinoma and BM who were treated with first-line EGFR-TKIs. The gene discussed is EGFR; the disease is lung adenocarcinoma.